Signalling success: Swiss MS Society campaign wins innovation award
The ‘Innovation of the Year’ fundraising award was presented in recognition of the Swiss MS Society’s 2017 World MS Day event, ‘We send a signal’.
European Medicines Agency recommends market authorisation for ocrelizumab (Ocrevus) in EU
The EMA has recommended that ocrelizumab (Ocrevus), the first disease-modifying treatment for primary progressive MS (PPMS), be prescribed for adults with early primary progressive MS
Highlights from World MS Day
A flavour of how global MS organisations marked World MS Day 2017
Improving quality of life for people with MS
Training programme led to significant improvements in manual dexterity